Skip to main content
LFMD
NASDAQ Industrial Applications And Services

LifeMD Reports Mixed Q4 Results, Guides for Q1 EBITDA Loss Amid Strategic Growth Investments

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Health Tech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$3.48
Mkt Cap
$150.184M
52W Low
$2.56
52W High
$15.84
52W Position info
36% above low
Off High info
78% below high
Rel. Volume info
2.2× avg
Market data snapshot near publication time

LFMD sits 36% above its 52-week low of $2.56 on elevated volume (2.2× avg).

Summary

LifeMD reported Q4 revenue below estimates and guided for a Q1 2026 Adjusted EBITDA loss due to strategic growth investments, but highlighted a strong debt-free balance sheet and robust long-term revenue and EBITDA run-rate projections.


Key Events · Earnings and Guidance · LFMD

  • Q4 2025 Revenue Miss

    Reported Q4 2025 revenue of $46.9 million, a 4% increase year-over-year, but falling short of analyst estimates.

  • Strong Balance Sheet

    Ended 2025 with $36.8 million in cash and no debt, providing significant financial flexibility for growth investments.

  • Q1 2026 Guidance for EBITDA Loss

    Forecasts Q1 2026 revenue of $48-$49 million but an Adjusted EBITDA loss of $4-$5 million, attributed to strategic front-loaded patient acquisition investments.

  • Strategic Growth Initiatives

    Successfully launched oral Wegovy and expanded women's health offerings, driving record patient sign-ups in Q1.


Analysis · LFMD · Industrial Applications And Services

LifeMD, Inc. reported fourth-quarter revenue that fell short of analyst estimates, and guided for an Adjusted EBITDA loss in Q1 2026 due to significant front-loaded investments in patient acquisition for its weight management (oral Wegovy) and women's health offerings. Despite the short-term profitability dip, the company exited 2025 with a strong balance sheet, including $36.8 million in cash and no debt. Management projects a return to profitability in Q2 2026 and anticipates strong annualized run-rate revenue exceeding $250 million and Adjusted EBITDA over $25 million by Q4 2026, driven by these strategic growth initiatives. Investors should monitor the execution of these growth strategies and the company's ability to achieve its ambitious Q4 2026 run-rate targets.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, LFMD was trading at $3.48 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $150.2M. The 52-week trading range was $2.56 to $15.84. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

LFMD - Latest Insights

LFMD
Nov 12, 2026, 4:58 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.61
Real-time Price: $1.60 info
Change: -$0.010 (-0.62%) info
Market Cap: $77.092M info
LFMD
Nov 12, 2026, 4:10 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.49
Real-time Price: $1.60 info
Change: +$0.110 (+7%) info
Market Cap: $77.092M info
LFMD
Nov 12, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $1.54
Real-time Price: $1.60 info
Change: +$0.0599 (+4%) info
Market Cap: $77.092M info
LFMD
Nov 09, 2026, 9:39 AM EST
Source: Reuters
Importance Score:
9
Price at Filing: $1.98
Real-time Price: $1.60 info
Change: -$0.380 (-19%) info
Market Cap: $77.092M info
LFMD
Sep 15, 2026, 10:18 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.30
Real-time Price: $1.60 info
Change: -$1.69 (-51%) info
Market Cap: $77.092M info